Grupo GSH (“GSH”), a leading healthcare services provider in Brazil, is pleased to welcome CVC Capital Partners IX as its new majority shareholder. The new partnership will continue GSH’s strong service level culture and accelerate growth in both its existing core markets and through expansion into new product categories and patient services. CVC Funds will acquire the business from Rede D’Or, the largest integrated health care network in Brazil, and from private equity fund Opus Investimentos, which have supported the development of GSH for more than eight years. GSH will remain as the main provider of hemotherapy services to Rede D’Or.
Headquartered in Rio de Janeiro, Brazil, GSH is a pioneer in Brazil’s hemotherapy and nuclear medicine space with leading market positions, delivering mission-critical services and products at an attractive value proposition to hospitals and diagnostic centres. The hemotherapy division serves 31,000 beds in +270 hospitals through long-term contracts providing blood collection, storage and transfusion services. The nuclear medicine division develops and services radiopharmaceutical products and solutions focused on diagnostics and therapeutics for hospitals, diagnostics and cancer centres in Brazil. Facilities include cold kit plant, radiopharmacies and cyclotrons.
Paulo Moll, CEO at Rede D’Or, said: “GSH has demonstrated RDSL’s ability to successfully develop complementary services that enhance our core hospital services, providing the very best care consistent with RDSL’s network. After eight years supporting and nurturing GSH it is time for the business to welcome a new investor to help accelerate its growth and we are delighted to welcome CVC as the new steward for the company. We look forward to working with them and to continuing to offer GSH’s high-quality services to our patients.”
Marcos Faccioli, GSH management representative, commented: “The interest of CVC in GSH confirms the success of our trajectory. A history built with the support of RDSL and Opus together with our employees, clients, suppliers and partners. We are very excited in welcoming CVC as the new majority shareholder and to work with the CVC team on the development of our business and on continuing to provide world class products and services to our clients and their patients.”
GSH represents CVC’s first healthcare investment in Latin America, building on our strong local presence in Brazil and our broad healthcare portfolio of over 25 businesses worldwide.
Fernando Pinto Partner and Head of Latin America at CVC
Fernando Pinto, Partner and Head of Latin America at CVC, added: “GSH represents CVC’s first healthcare investment in Latin America, building on our strong local presence in Brazil and our broad healthcare portfolio of over 25 businesses worldwide. We are excited to partner with GSH’s management team to continue strengthening its high-quality hemotherapy and fast-growing nuclear medicine services, while also expanding into new complementary areas. We are proud to have been selected as GSH’s next long-term partner.”
The closing of the transaction is subject to approval by the relevant regulatory authorities and is expected in Q3 2025.